---
title: "Lifeon Pharmaceutical: Received the Clinical Trial Approval Notice for Drugs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237337939.md"
description: "Lifeon Pharmaceutical announced that it has received the clinical trial approval notice for Beipaidu Acid Tablets from the National Medical Products Administration. Beipaidu Acid Tablets are an adenosine triphosphate - citrate lyase inhibitor designed to lower LDL-C by inhibiting cholesterol synthesis in the liver. The drug was approved in the United States in 2020 and has not yet been launched domestically. This registration application is classified as a Class 3 chemical drug, making Lifeon Pharmaceutical the third company in the country to receive clinical approval. This approval will have little impact on the company's short-term performance"
datetime: "2025-04-24T09:30:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237337939.md)
  - [en](https://longbridge.com/en/news/237337939.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237337939.md)
---

# Lifeon Pharmaceutical: Received the Clinical Trial Approval Notice for Drugs

Lifeon Pharmaceutical announced that the company has received the "Drug Clinical Trial Approval Notice" for Beipaidu Acid Tablets issued by the National Medical Products Administration. Beipaidu Acid Tablets are an adenosine triphosphate-citrate lyase inhibitor that lowers LDL-C by inhibiting cholesterol synthesis in the liver. The original research drug was approved for marketing in the United States in 2020 and has not yet been launched domestically. This registration application is classified as a Class 3 chemical drug. According to data from the Drug Evaluation Center of the National Medical Products Administration, the company is the third domestic enterprise approved for clinical trials. The approval of the clinical trial application for Beipaidu Acid Tablets will not have a significant impact on the company's short-term performance

### Related Stocks

- [003020.CN](https://longbridge.com/en/quote/003020.CN.md)

## Related News & Research

- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [REG - Nomura Intl. PLC Spire Healthcare Grp - Form 8.3 - SPIRE HEALTHCARE GROUP PLC](https://longbridge.com/en/news/296096467.md)
- [13:22 ET/C O R R E C T I O N -- Rayence/](https://longbridge.com/en/news/296256530.md)
- [15:32 ETMedical Solutions ranks among nation's Top 5 largest healthcare staffing firms](https://longbridge.com/en/news/296139102.md)
- [Singapore's OUE strengthens China presence with Shenzhen flagship](https://longbridge.com/en/news/296056716.md)